NASDAQ
2.15USD
+0.16 (+8.04%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
387.2M
P/E
—
EPS
—
Beta
0.82
52W range
1.61-6.88
Day range
2.03–2.17
Open
2.05
Prev close
1.99
Volume
3.8M
Avg volume
7.6M
Dividend
0.00
IPO
2021-04-05
https://seekingalpha.com/article/4922386-compass-therapeutics-a-50-percent-price-cut-hiding-a-regulatory-mispricing-opportunity · 7/15/2026+0.20
https://www.globenewswire.com/news-release/2026/05/21/3299774/0/en/Compass-Therapeutics-to-Present-Promising-Phase-1-Clinical-Data-for-CTX-8371-in-Patients-with-Advanced-Malignancies-Treated-in-the-Post-Checkpoint-Inhibitor-Setting-at-the-2026-ASC.html · 5/21/2026+0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-compass-therapeutics-inc---cmpx-302759522.html · 4/30/2026-1.00
https://seekingalpha.com/article/4894604-compass-therapeutics-inc-cmpx-discusses-positive-secondary-endpoint-results-from · 4/27/2026+0.80
https://www.defenseworld.net/2026/04/12/compass-therapeutics-inc-nasdaqcmpx-receives-consensus-rating-of-moderate-buy-from-brokerages.html · 4/12/2026+0.60
https://www.fool.com/coverage/filings/2026/03/02/investment-advisor-bets-big-on-cmpx-stock-adds-2-5-million-shares-according-to-latest-sec-filing/ · 3/2/2026+0.60
https://www.zacks.com/stock/news/2823468/wall-street-analysts-see-an-113-73-upside-in-compass-therapeutics-inc-cmpx-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2823468 · 1/27/2026+0.80
https://seekingalpha.com/article/4859816-compass-therapeutics-inc-cmpx-presents-at-44th-annual-j-p-morgan-healthcare-conference · 1/14/2026+0.10
https://seekingalpha.com/article/4850467-compass-therapeutics-inc-cmpx-presents-at-evercore-8th-annual-healthcare-conference · 12/4/2025+0.00
https://www.globenewswire.com/news-release/2025/11/03/3179225/0/en/Compass-Therapeutics-to-Participate-in-Upcoming-November-Investor-Events.html · 11/3/2025+0.30
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
